About us

Energenesis Biomedical Announces Positive End-of-Phase 2 Meeting with FDA on ENERGI-F703 for the Treatment of Diabetic Foot Ulcers

Energenesis Biomedical and the U.S. Food and Drug Administration (FDA) reach agreements on key elements necessary for regulatory approval, clearing a path to initiate the global phase 3 study in diabetic foot ulcer patients. The Phase 3 design was supported by the encouraging results from a Phase 2 study of ENERGI-F703. Energenesis Biomedical is on track to launch the global phase 3 study in 2022.